Oncotelic Therapeutics, Inc. (OTCPK: OTLC)
Health Care · Biotechnology · US
$0.04
-14.91% today · -30.4% 1Y
Oncotelic Therapeutics, Inc. (OTCPK: OTLC) operates in the Biotechnology industry within the Health Care sector. The company is valued at $16.97M and employs 41 people.
Over the last twelve months the share price has lost 30.4%, trading between 0.02 and 0.11.
Tweenvest scores Oncotelic Therapeutics, Inc. across four factors: quality 27/100, value 28/100. Its strongest factor is value.
OTLC price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $16.97M
- Revenue (TTM)
- $250.00K
- P/E
- 0.07
- EPS
- 0.56
- Dividend yield
- —
- Beta (5Y)
- -0.21
- 52-week high
- $0.11
- 52-week low
- $0.02
- Avg volume (3M)
- —
- Shares outstanding
- 457.51M
- Employees
- 41
- Next earnings
- —
About Oncotelic Therapeutics, Inc.
Oncotelic Therapeutics, Inc., an Agoura Hills, California-based clinical-stage biopharmaceutical company, specializes in developing therapeutics for rare oncological conditions. Its flagship therapeutic candidate, OT-101 – an antisense compound designed to inhibit TGF-ß2 – is currently undergoing Phase 3 clinical trials for both pancreatic cancer and glioblastoma. Beyond oncology, OT-101 is also being explored for its potential in treating various viral diseases, including severe acute respiratory syndrome (SARS) and coronaviruses. The company's pipeline further includes OXi4503, which is being advanced for acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), and CA4P, intended for the treatment of advanced metastatic melanoma.
- ISIN
- US6283411097
- Listed since
- Aug 26, 1993
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €883.80 | -2.02% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $142.62 | -1.69% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.